
Reviewers report that the dossiers submitted regarding the use of Apremilast for psoriasis contained neither data from studies of direct comparisons nor indirect comparisons. The manufacturer itself also did not claim an added benefit for its new drug, they conclude.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/ADllTVnou6E/150519105711.htm